Rosetta Genomics Announces First Source for Clinical Validation of its Cancer of Unknown Primary (CUP) Diagnostic Test

Samples Will be Analyzed Using Proprietary miRdicator(TM) Technology

May 01, 2007, 01:00 ET from Rosetta Genomics Ltd

    REHOVOT, Israel and DETROIT, Michigan, May 1 /PRNewswire-FirstCall/ --
 Rosetta Genomics (Nasdaq:  ROSG) announced today that it has signed an
 agreement with the Henry Ford Hospital in Detroit, Michigan, one of the
 world's leading research centers for brain cancer, to provide the company
 with samples of metastases found in brain tissue. The samples will then be
 analyzed using Rosetta Genomics' proprietary miRdicator(TM) technology to
 determine the origin of the metastasis.
     "This is a significant step towards initiating the clinical validation
 for our cancer of unknown primary diagnostic test, "said Amir Avniel,
 President and CEO of Rosetta Genomics. "The samples we will receive from
 the Henry Ford Hospital will help validate our lead diagnostic program and
 advance it forward towards launching the first microRNA-based diagnostic
     The brain is one of the leading sites where metastases of unknown
 origin are found. Rosetta Genomics CUP test is designed to identify the
 site where the metastasis originated by analyzing the unique microRNA
 signature of each metastasis and comparing it to the signature of known
 primary sites.
     "Our CUP diagnostic program has been showing rapid progress over the
 past few months," noted Dalia Cohen, Rosetta Genomics' Global Head of R&D.
 "We are continually expanding the test, and believe we have reached a point
 where we can confidently begin running "blind" samples of metastases on our
 miRdicator(TM) platform to identify their origin."
     About Cancer of Unknown Primary (CUP)
     Cancer of Unknown Primary (CUP) - In 3% to 5% of new cancer cases, the
 site of origin of a tumor cannot be readily identified, or a diagnosis of
 origin is equivocal. This disease manifestation is known as a cancer of
 unknown primary (CUP). These tumors represent a clinically diverse group,
 typically presenting with moderately to poorly differentiated tumors, often
 adenocarcinoma, involving multiple organs including liver, bone, brain,
 lung, lymph nodes and pleura. Patients with CUP represent a
 disproportionate fraction of cancer deaths due to their poor median
 survival, often measured in months. In many cases, patients receive a
 series of sequential treatments before a response, if any, is obtained. A
 large proportion of cases remain undiagnosed, with the result that therapy
 cannot be matched to their specific disease.
     About microRNAs
     MicroRNAs (miRNAs) are a recently discovered, naturally occurring form
 of RNAi. These small RNAs act as protein regulators and have the potential
 to form the basis for a new class of diagnostics and therapeutics. Since
 many diseases are caused by the abnormal activity of proteins, the ability
 to selectively regulate protein activity through microRNAs could provide
 the means to treat a wide range of human diseases. In addition, microRNAs
 have been shown to have different expression levels in certain diseased
 versus normal tissues. As a result, these differences potentially provide
 for a novel diagnostic strategy for many diseases. MicroRNAs are thought to
 play a key role in the differentiation of cells into specific cell types
 performing various functions in the body.
     About Henry Ford Hospital
     Henry Ford Hospital is a 903-bed tertiary care hospital, education and
 research complex in Detroit's New Center Area. The hospital is recognized
 for clinical excellence and innovation in the fields of neurology and
 neurosurgery, cardiology and cardiovascular surgery, orthopedics and sports
 medicine, organ transplants, and treatment for prostate, breast and lung
 cancers. HFH is a Level 1 trauma center.
     About Rosetta Genomics
     Rosetta Genomics (Nasdaq:   ROSG) is a leader in the development of
 microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
 integrative research platform combining bioinformatics and state-of-the-art
 laboratory processes has led to the discovery of hundreds of biologically
 validated novel human microRNAs. Building on its strong IP position and
 strategic alliances with leading biotechnology companies, Rosetta Genomics
 is working to develop a full range of diagnostic and therapeutic products
 based on microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     Forward-Looking Statement Disclaimer
     Various statements in this release concerning Rosetta's future
 expectations, plans and prospects, including without limitation, statements
 relating to our ability to successfully develop a microRNA-based diagnostic
 test for CUP, the role of miRNAs in human physiology and disease, and the
 potential of microRNAs in the diagnosis and treatment of disease,
 constitute forward-looking statements for the purposes of the safe harbor
 provisions under The Private Securities Litigation Reform Act of 1995.
 Actual results may differ materially from those indicated by these
 forward-looking statements as a result of various important factors,
 including risks related to: Rosetta's approach to discover and develop
 novel diagnostics products, which is unproven and may never lead to
 marketable products; Rosetta's ability to fund and the results of further
 pre-clinical and clinical trials; obtaining, maintaining and protecting
 intellectual property utilized by Rosetta's products; Rosetta's ability to
 enforce its patents against infringers and to defend its patent portfolio
 against challenges from third parties; Rosetta's ability to obtain
 additional funding to support its business activities; Rosetta's dependence
 on third parties for development, manufacture, marketing, sales, and
 distribution of products; the successful development of Rosetta's product
 candidates, all of which are in early stages of development; obtaining
 regulatory approval for products; competition from others using technology
 similar to Rosetta's and others developing products for similar uses;
 Rosetta's dependence on collaborators; and Rosetta's short operating
 history; as well as those risks more fully discussed in the "Risk Factors"
 section of Rosetta's most recent Registration Statement on Form F-1 on file
 with the Securities and Exchange Commission. In addition, any
 forward-looking statements represent Rosetta's views only as of today and
 should not be relied upon as representing its views as of any subsequent
 date. Rosetta does not assume any obligation to update any forward-looking
 statements unless required by law.
     Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785

SOURCE Rosetta Genomics Ltd